Impact of the implementation of a Fracture Liaison Service on pharmaceutical expenses for osteoporosis compared to an area without an FLS
| Autor: | Amparo Molina, Aida Saavedra, Soledad Ojeda-Bruno, Antonio Naranjo, Miguel Ángel Negrín |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
musculoskeletal diseases Cost-Benefit Analysis Osteoporosis Decision Support Techniques 03 medical and health sciences 0302 clinical medicine Secondary Prevention medicine Humans Pharmacology (medical) Operations management 030212 general & internal medicine Least-Squares Analysis skin and connective tissue diseases health care economics and organizations Aged Aged 80 and over Service (business) Secondary prevention Bone Density Conservation Agents Diphosphonates Hip Fractures business.industry 030503 health policy & services Health Policy Interrupted Time Series Analysis General Medicine Middle Aged musculoskeletal system medicine.disease Fracture (geology) Female 0305 other medical science business Decision model Osteoporotic Fractures |
| Zdroj: | Expert Review of Pharmacoeconomics & Outcomes Research. 19:81-87 |
| ISSN: | 1744-8379 1473-7167 |
| DOI: | 10.1080/14737167.2018.1513791 |
| Popis: | Fracture Liaison Service (FLS) model for secondary prevention of fractures has demonstrated its cost-effectiveness using decision models. We analyze the impact of a FLS on pharmaceutical expenditures for osteoporosis (OP) in real-world circumstances.Expenditures on OP medications from January 2011 to January 2017 were compiled. Pharmaceutical expenditures in the southern area of Gran Canaria were used as a control group to measure the impact of implementing an FLS in the northern area. We estimated generalized least squares regressions with interrupted time-series analysis where two interventions were considered: March 2012 (implementation of the FLS) and March 2016 (incorporation of nursing staff for inpatients with hip fracture).The northern area incurred greater expenditures for group I and II drugs. The difference in bisphosphonates expenditures between areas varied from 10.5% higher in the northern area pre-FLS to 11.2% post-FLS and 18.3% since March 2016. However, interrupted time series models do not find a significant impact of implementation of FLS on the pharmaceutical expenditures for either drug group.The implantation of an FLS did not lead to an increase in pharmaceutical expenditures for OP over the 5-year period compared to the standard care provided for secondary fracture preventions. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|